Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 481-490 of 2762 for cancer

Edit search filters
  1. Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Phase I/​II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/​Without Prior 177Lu-PSMA RLT

    Rochester, MN

  3. Safety and Preliminary Efficacy of OBT076 in Recurrent/​Metastatic CD205+ Solid Tumors

    Scottsdale/Phoenix, AZ

  4. Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

    Rochester, MN

  5. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study to Evaluate Chemoradiotherapy with or without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

    La Crosse, WI, Eau Claire, WI, Scottsdale/Phoenix, AZ, Rochester, MN

  7. Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

    Rochester, MN

  8. Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

    Rochester, MN

  9. Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

    Rochester, MN

  10. A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer